US President Donald Trump has announced a new tariff regime for pharmaceuticals, opening a fresh front in his trade policy by targeting imported patented medicines with duties that can rise to 100 per cent.
The measure, unveiled on 2 April 2026, is intended to pressure drugmakers either to lower prices in the United States, conclude pricing agreements with Washington, or expand manufacturing capacity on American soil.
Under the White House proclamation, the 100 per cent duty will apply to patented pharmaceutical products and related ingredients listed by the administration, subject to a series of exemptions and transitional arrangements. Generic medicines are excluded. Companies that have already entered into pricing agreements with the US government, or that secure exemptions through other arrangements, will avoid the highest rate. The administration is presenting the move as both a price-control mechanism and an industrial policy tool aimed at reducing dependence on foreign pharmaceutical production.
The policy is not being applied uniformly. Countries that have concluded trade arrangements with Washington, including the European Union, Japan, South Korea and Switzerland, are set to face lower tariff rates of 15 per cent on covered pharmaceutical imports rather than the full 100 per cent. The United Kingdom has secured more favourable treatment still. Britain finalised a pharmaceutical trade agreement with the US that gives British-made medicines tariff-free access to the American market for at least three years.
The administration has also created a limited transition pathway for manufacturers planning to move or expand production in the United States. Companies that are building domestic manufacturing facilities can apply for a temporary 20 per cent tariff rate during a four-year adjustment period rather than facing the full penalty immediately. The grace period before implementation will vary by company size, with large pharmaceutical groups facing the new regime in 120 days and smaller firms in 180 days.
Trump’s move comes one year after the tariff package he branded “Liberation Day”, when he announced broad “reciprocal tariffs” against trading partners. Since then, his administration has retreated from some earlier measures after legal and political setbacks. On 20 February 2026, the US Supreme Court struck down a large part of Trump’s previous global tariff programme imposed under the International Emergency Economic Powers Act, ruling that the statute did not give the president the sweeping authority he claimed. That decision forced the administration to pursue alternative legal routes, including Section 232 national security powers, to maintain parts of its tariff agenda.
The pharmaceutical announcement was accompanied by a parallel adjustment to metals duties. The White House said it would revise the tariff treatment of some steel, aluminium and copper products, including reducing duties on many derivative goods and simplifying the method used to calculate tariff liability. Many such derivative products would see their tariff rate cut to 25 per cent, while items containing less than 15 per cent metal by weight would face no added duty. The administration said the changes were intended to simplify enforcement and address problems linked to under-reporting of import values.
For the pharmaceutical sector, the implications are potentially significant. The new tariffs are aimed primarily at branded and patented medicines, which are often among the most profitable products in multinational supply chains. By exempting generics, Washington appears to be trying to avoid the broadest disruption to lower-cost medicine supply while preserving leverage over high-value proprietary drugs. That approach may reduce the immediate impact on some parts of the market, but it still places substantial pressure on large manufacturers operating across Europe, Asia and other export-oriented production hubs.
The move is also likely to intensify disputes over drug pricing between Washington and allied governments. The UK agreement illustrates the kind of bargain the Trump administration is seeking: tariff relief in exchange for changes to domestic pricing and spending rules. Reuters reported that, under the US-UK deal, Britain agreed to raise the prices paid by the National Health Service for new medicines and to increase overall medicine spending targets over time. That arrangement is likely to be studied closely in Brussels, Tokyo, Seoul and Bern as governments assess how far Washington intends to tie trade access to pharmaceutical pricing policy.
Critics argue that tariffs on medicines carry obvious economic and public health risks, including the possibility of higher costs and supply disruption. Industry representatives have already warned that the measures could raise costs in healthcare and complicate investment planning. Supporters inside the administration, however, argue that the combination of tariffs, pricing demands and local investment incentives will force drugmakers to shift production to the US and reduce the gap between American medicine prices and those paid in other developed markets.
Whether the policy survives legal scrutiny and achieves its stated aims remains uncertain. What is clear is that Trump has now placed pharmaceuticals alongside metals, autos and other sectors at the centre of a trade strategy that increasingly combines tariffs with negotiated exemptions and domestic investment demands.
